2023年第46届圣安东尼奥乳腺癌研讨会（San Antonio Breast Cancer Symposium，SABCS）将于12月5日至9日在美国得克萨斯州圣安东尼奥举行。该会议汇聚了全球约1万名临床医生和专家，是规模最大、最具影响力的乳腺癌研究盛会。
日前，大会公布了本次会议的详细日程及研究题目，150余项中国研究成果入选SABCS。【肿瘤资讯】从官网获得现有资讯，将入选POSTER session 1的中国研究信息整理如下，以飨读者。
PO1-01-02 Final analysis of neoadjuvant chemotherapy with pegylated liposomal doxorubicin/cyclophosphamide followed by taxanes with full-course trastuzumab/pertuzumab for HER2-positive breast cancer: a single-arm, phase II study.
作者：Yaping Yang，Liang Jin，Yudong li，Fengxia Gan， Nanyan Rao，Jun Zhang，Ruifa feng，Zhenzhen Liu，Qiang Liu
第一作者单位：Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
PO1-01-04 The optimal neoadjuvant treatment regimen for HR+/HER2+ breast cancer: a network meta-analysis.
作者：Hao Wang，Shiwei Liu，Miao Yu，Kun Mi，Exian Mou，Li Xia，Weimin Xie ，Hao Tang，Yajing Feng，Xin Yu
第一作者单位：Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, People's Republic of China
PO1-03-11 Camrelizumab in Combination with Nab-Paclitaxel and Carboplatin versus Nab-Paclitaxel and Carboplatin as Neoadjuvant Therapy for Triple Negative Breast Cancer: A Multicenter, Open-Label, Randomized Controlled Study.
作者：Weipeng Zhao，Xin Wang，Bin Zhang，Yehui Shi，Chen Wang，Xu Wang，Shufen Li，chunfang Hao，Ning Lu，Yongsheng Jia，Li Zhang，Lan Zhang，Weixin Sun，Xuchen Cao，Zhongsheng Tong
第一作者单位：Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
PO1-04-04 Inetetamab combined with pyrotinib and oral vinorelbine for patients with HER2-positive metastatic breast cancer: a single-arm phase 2 trial.
作者：Xiang huang，Nan Jin，Chunxiao Sun， Xueqi Yan，Fan Yang，Yan Liang，Wei Li，Yongmei Yin
第一作者单位：Jiangsu hospital the first affiliated hospital with Nanjing medical university
PO1-04-05 Effectiveness and safety of inetetamab + pyrotinib + vinorelbine in ≥second-line treatment of HER2-positive metastatic breast cancer.
作者：Fan wu，Mulan Chen，Weiwei Huang，Lili Wang， Nani Li，Xiufeng Wu，Xinhua Chen，Yi Hong，Lin Lin，Kan Chen，Jian liu
第一作者单位：Department of Medical Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
PO1-05-11 Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer: a retrospective cohort study.
作者：Ren Chongxi，Sun Jianna，Kong Lingjun，Hongjun Yu
第一作者单位：Cangzhou Clinical College of Integrated Traditional Chinese and Western Medicine of Hebei Medical University, China (People's Republic)
PO1-06-01 Clinical Efficacy of Tumor Organoid-Guided Cancer Therapy for Locally Advanced Unresectable or Metastatic Breast Cancer.
作者：Ying-Yi Lin，Hong-Fei Gao，Hong Li，Bo-Lei Du， Min-Yi Cheng，Jia-Chen Zou，Xing-xing Zheng，Teng Zhu，Ting-ting Li，Sheng Li，Kun Wang
第一作者单位：Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
PO1-06-05 Heterogeneity and prognostic characteristics of HER2-low breast cancer: A retrospective analysis of patients with HER2-negative metastatic breast cancer.
作者：Huimin Lv，Min Yan，mengwei zhang，Limin Niu，Huiai zeng，Huihui Sun，shengnan zhao，jing wang
第一作者单位：Department of Breast Disease, Henan Breast Cancer Center. The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, China (People's Republic)
PO1-06-07 EMSY enhances cancer stem cell self-renewal and tumorigenesis by reshaping methionine metabolism in triple-negative breast cancer.
作者：Cui-Cui Liu，Ke-da Yu
第一作者单位：Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University
PO1-06-10 Overall survival results from EVER-132-001, a phase 2b single-arm study of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer.
作者：Fei Ma，Shusen Wang ，Zhongsheng Tong，Wei Li，Xinhong Wu，Xiaojia Wang，Tao Sun，Yueyin Pan，Herui Yao，Xian Wang，Ting Luo，Jin Yang，Xiaohua Zeng，Weihong Zhao，Kimberly Komatsubara，Rachel Nakamura，Catherine Lai，Bo Zhang，Xiuyu Cong，Binghe Xu
第一作者单位：Cancer Hospital, Chinese Academy of Medical Sciences, China
PO1-06-11 Exosomal HMGB1 induce PD-L1+-tumor associated macrophages through glycometabolic reprogramming to promote lung-tropic metastasis of triple negative breast cancer.
作者：Wei-xian Chen，Jia-hao Wu，Tian-cheng Cheng，Sujin Yang
第一作者单位：Department of Breast Surgery, the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou 213000, Jiangsu Province, China, Changzhou, Jiangsu, China (People's Republic)
PO1-06-12 Phase II study of sitravatinib plus tislelizumab with or without nab-paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer.
作者：Lei Fan，Xiyu Liu，Ying Xu， Xinyi Sui，Wenjuan Zhang，Linxiaoxi Ma，Xi Jin，Song-Yang Wu，Han Wang，Yi Xiao， Li Chen，Jiong Wu，Ke-da Yu，Guangyu Liu，Xin Hu，Zhonghua Wang，Yi-Zhou Jiang， Zhi-Ming Shao
第一作者单位：Fudan University Shanghai Cancer Center, Shanghai, China (People's Republic)
PO1-07-04 Multiomics analysis reveals the landscape of PD-L1 expression in triple-negative breast cancer.
作者：Han Wang，Xiao-Hong Ding，Cheng-Lin Liu，Yi Xiao，Ruo-Hong Shui，Yan-Ping Li ，Chen Chen，Wen-Tao Yang，Zhi-Ming Shao，Yi-Zhou Jiang
第一作者单位：Fudan University Shanghai Cancer Center
PO1-07-07 Radiomics features for distinguishing true recurrence versus new primary tumor following breast-conserving treatment.
作者：Feilin Qu，Guan-Hua Su，Jin-Hui Li，Chao You，Zhi-Ming Shao
第一作者单位：Fudan University Shanghai Cancer Center
PO1-07-11 Radiogenomic-based imaging intratumor heterogeneity model predicts breast cancer prognosis and unveils therapeutic targets.
作者：Guan-Hua Su，Yi Xiao，Chao You，Ren-Cheng Zheng ，Shen Zhao，He Wang，Yi-Zhou Jiang，Ya-Jia Gu，Zhi-Ming Shao
第一作者单位：Fudan University Shanghai Cancer Center
PO1-08-05 Using the CTS5 Score to Predict Late Recurrence in Male and Female Estrogen Receptor- Positive Breast Cancer Patients: a SEER database analysis of 65,729 cases.
作者：Fenhua Wang，Fang Ren， Jian Qian， Yunxia Xu，Jiayi Wu，Yu Zong，Xidong Gu
第一作者单位：Hangzhou Linping Maternal and Child Health Hospital
PO1-10-09 The Performance Of Mobile Units Versus Hospital Units In National Breast Cancer Screening Program In Taiwan, 2010-2020.
作者：Vy Vu，Amy Ming-Fang Yen，Melissa Min-Szu Yao， Wing P. Chan
第一作者单位：International PhD Program in Medicine, Taipei Medical University, Taipei, Taipei, Taiwan (Republic of China)
PO1-11-12 Factors associated with treatment failure for chemotherapy-induced nausea and vomiting (CINV) among breast cancer patients receiving adjuvant chemotherapy.
作者：Winnie Yeo，Nicole Ngai， Horatio Yeo，Dong Lai，Elizabeth Pang，Carol Kwok，Thomas Lau，Frankie Mo
第一作者单位：Chinese University of Hong Kong, Hong Kong
PO1-13-01 Safety profiles of Chinese breast cancer patients who received abemaciclib in MONARCH plus and monarchE study.
作者：Zhimin Shao，Qingyuan Zhang，Quchang Ouyang，Qiang Liu， Jifeng Feng，Hui-Ping Li，Xiaojia Wang，Ning Liao，Liu Yang，Qinyi Zhu，Chenxi Qian， Zefei Jiang
第一作者单位：Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, China (People's Republic)
PO1-13-05 Genomic characteristics and its therapeutic implications in breast cancer patients with detectable molecular residual disease.
作者：xu yan，Shu Zhang，Lu zhou，Yan Jiang，Jing Xu， Gang Zhang，Lu Shen
第一作者单位：Department of Breast and Thyroid Surgery, Daping Hospital, Army Medical University, China (People's Republic)
PO1-13-11 ZNF689 promotes homologous recombination via NBS1 ubiquitination and its loss confers sensitivity to PARP inhibition in triple-negative breast cancer.
作者：Li-Ping Ge，Zi-Yu Wang，Xi Jin， Yi-Zhou Jiang，Zhi-Ming Shao
第一作者单位：Fudan University Shanghai Cancer Center
PO1-13-12 Mechanistic Analysis and Potential Therapeutic Implications in Breast Cancer with Fibrotic Focus.
作者：Canbin Fang，Julia Y. S. Tsang，Gary M.K. Tse
第一作者单位：The Chinese University of Hong Kong
PO1-14-03 Discovery of proliferation essential gene signature and ACTL6A as potential biomarker for predicting prognosis and neoadjuvant therapy response in triple-positive breast cancer.
作者：Xiaofen Li， Wenfen Fu，Shiping Luo，Jie Zhang，Qingshui Wang，Chuangui Song
第一作者单位：Fujian Cancer Hospital
PO1-14-06 Integrated analysis reveals the impact of obesity on triple-negative breast cancer.
作者：Yue Gong ，Peng Ji，Huai-liang Wu，Li-Hua He，Ming-Liang Jin，Xin Hu，Yi-Zhou Jiang，Zhiming Shao
第一作者单位：Fudan University Shanghai Cancer Center
PO1-14-07 Programme of mast cell subsets to potentiate breast cancer immunotherapy: from bed to bench to bed (the phase 2 platform RENAISSANCE trial).
作者：Song-Yang Wu，Xi Jin，Yin Liu，Wen- Jia Zuo，Li Chen，Xiyu Liu，Lei Fan，Zhong-Hua Wang，Yan-Fei Liu，Yi-Zhou Jiang，Zhi- Ming Shao
第一作者单位：Fudan University Shanghai Cancer Center, China (People's Republic)
PO1-15-02 Comprehensive characterization of genetic interactions in breast cancer reveals therapeutic vulnerabilities.
作者：Caijin Lin，Xi Jin，Ding Ma，Chao Chen，Xin Hu，Yi-Zhou Jiang ，Zhi-Ming Shao
第一作者单位：Fudan University Shanghai Cancer Center
PO1-15-07 Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial.
作者：Xiu-Zhi Zhu，Xi Jin，Hu-Yun- Long Zhang，Xiyu Liu，Yi-Fan Zhou，Yi-Yu Chen，Tong Fu，Ming-Liang Jin，Ya-Xin Zhao ，Yi-Fan Xie，Ruo-Xi Wang，Zhong-Hua Wang，Lei Fan，Yi-Zhou Jiang，Zhi-Ming Shao
第一作者单位：Fudan University Shanghai Cancer Center
PO1-15-08 Genomic characterization of triple-negative breast cancer metastases reveals PKD1 as a novel biomarker for immunotherapy.
作者：Xiu-Zhi Zhu，Yi-Fan Zhou，Yun-Yi Wang，Xiao-Hong Ding ，Xi Jin，Zhi-Ming Shao，Yi-Zhou Jiang，Zhong-Hua Wang
第一作者单位：Fudan University Shanghai Cancer Center
PO1-15-09 Vitamin A Metabolism Induces Ferroptosis to Enhance Immune Therapy Efficacy in HR+/HER2- Breast Cancer.
作者：Yi-Fan Zhou，Hu-Yun-Long Zhang，Xi Jin，Yi-Zhou Jiang，Zhi-Ming Shao
第一作者单位：Fudan University Shanghai Cancer Center, Shanghai, China (People's Republic)
PO1-16-03 GDP-mannose enhances the efficacy of PARP inhibitors and immunotherapy in triple- negative breast cancer.
作者：Yi Xiao，Jiahan Ding，Yi-Zhou Jiang，Zhi-Ming Shao，Genhong Di， Fan Yang，Xiaoqing Song
第一作者单位：Fudan University Shanghai Cancer Center
PO1-16-09 Does T1c-2N0-1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?.
作者：Jie Zhang，Yushuai Yu，Weiwei Chen，Wenfen Fu，Ruiliang Chen，Jialu Yi ，Chuangui Song
第一作者单位：Fujian Medical University Union Hospital
PO1-17-01 Surgical Margins and prognosis of borderline and malignant phyllodes tumors of breast.
作者： lu Gan，Jialin Su
第一作者单位：The First Affiliated Hospital of Chongqing Medical University, Chongqing, China (People's Republic)
PO1-17-03 Real-world evidence of Trastuzumab biosimilars in HER2-positive breast cancer: Evaluating utilization, efficacy, and safety in Taiwan.
作者：Yi-Hung Lo，Yen-Dun Tzeng
第一作者单位：Department of General Surgery, Kaohsiung Veterans General Hospital
PO1-19-04 Dalpiciclib and tucidinostat in patients with HR+/HER2- advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial.
作者：Tao Wang，Jinmei Zhou，Xuexue Wu，Zefei Jiang
第一作者单位：The Fifth Medical Center of PLA General Hospital
PO1-22-08 Ductal Lavage versus Oral Corticosteroids in Patients with Idiopathic Granulomatous Mastitis: A Multicenter, Open-label, Randomized, Controlled, Non-inferiority Study.
作者：Kai Chen， Xiaolin Chen，Shunrong Li，Liling Zhu，Jian Zhang，Tingting Hu，Hui Huang，Heng Huang ，Lili Chen，Qiaozhen Xiao，Linhong Su
第一作者单位：Breast Tumor Center，Sun Yat-sen Memorial Hospital,，Sun Yat-sen University
PO1-22-09 Current margin assessment practice for breast-conserving surgery in China: a single institution audit.
作者：Feilin Qu，Cheng-Jia Shen，Wen-Tao Yang，Jun-Jie Li，Guangyu Liu，Zhi- Ming Shao
第一作者单位：Fudan University Shanghai Cancer Center
PO1-23-08 Exosome-based delivery of microRNAs confers adriamycin-resistance to sensitive cells through modulating the immune and metabolism-related gene PTEN in HER2-negative breast cancer.
作者：Sujin Yang，Tian-cheng Cheng，Jia-hao Wu，Wei-xian Chen
第一作者单位：The First Affiliated Hospital with Nanjing Medical University
PO1-23-10 Multi-omics analysis identifies the mechanism in cross-resistance to endocrine therapy and CDK4/6 inhibitor in breast cancer.
作者：Ming-Feng Hou，Chung-Liang Li，Chih-Po Chiang
第一作者单位：Kaohsiung Medical University Hospital, Kaohsiung, Taiwan (Republic of China)
PO1-24-01 ADAR1 drives ribosomal biogenesis by regulating NOP14 and stabilizing FBL-NOP58 complex in breast cancer.
作者：Liren Wangxu，Hengyu Ren，Zhibo Shao，Jiong Wu，Yayun Chi
第一作者单位：Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai. Department of Oncology, Fudan University Shanghai Medical College
PO1-25-04 PTN-positive luminal progenitors induce angiogenesis and metastasis in inflammatory breast cancer.
作者：Mengmeng Zhang，Kaiwen Zhou，Ting Liu，Filipa Lynce，Filipa Lynce， Wendy Chen，Qianjun Chen，Xiaoping Li，Zhongyu Yuan，Juan Xu，Zhenhai Cai， Jianping Guo，nan shao，Ying Lin
第一作者单位：Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, China (People's Republic)
PO1-27-01 Comparing the Efficacy and Safety of TQB2440 versus the Reference Pertuzumab for the Treatment of HER2-Positive Early or Locally Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase 3 Trial.
作者：Qingyuan Zhang，Shusen Wang，Nanlin Li， Qiao Cheng，Yu ren，Xuchen Cao，Jianjun Huang，Caigang Liu，Hongwei Yang，Limin Wei，Zhangjun Song，Huadong Zhao，Fangling Ning，Xiaojia Wang，Dehong Zou， Xiaohua Zeng，Jie Hao，Yunjiang Liu，Huijuan Wang，nie jianyun， Liang Li，LinaLiu，Tao Sun ，Xiaobo Hu，Zhenhua Zhai，Huihua Xiong ，Yuanqi Zhang，Enxiang Zhou，jing sun， Zhenhai Cai，Antai Zhang，Shui Wang， Junyang Mo，Qun Su，Xiuheng Qi，Guoren zhou，Shuqun Zhang，Guozhong Cui，Wei Wang，Mingjiang Fan，Xinyu Qian， Xinhong Wu，Zhihong Wang，Jiuda zhao，Yonghui Luo ，Yanming Zhang，Fuguo Tian，Jiye Zhang， Dongning Chai，Qingshan Li
第一作者单位：Harbin Medical University Cancer Hospital
PO1-27-04 A Multi-center Randomized Phase II Study of Doxorubicin Liposome Versus Epirubicin Plus Cyclophosphamide Combined With Trastuzumab and Pertuzumab (HP) Followed by THP as Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
作者：Wen XIA，Zhongyu Yuan，Zhiyong Wu，Muyi Zhong，Ying Wang，Xiaopeng Ma，Shihui Ma，Yuanqi Zhang，Lehong zhang ，Heng Huang，Xiangdong Xu，Haiyan Li
第一作者单位：Sun yet-sen University Cancer Center
PO1-27-05 De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab in HER2-positive early breast cancer (HELEN-006):a randomized,phase 3 trial.
作者：Zhenzhen Liu，Xiuchun Chen，Jianghua Qiao，Jiao Dechuang，Chengzheng Wang，Xianfu Sun，Zhenduo Lu，Lianfang Li，Chongjian Zhang，Min Yan，Ya Wei，Chen Bo，Yueqing Feng，Miao Deng， Mingde Ma
第一作者单位：Department of Breast Disease, Henan Breast Cancer Center. The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
PO1-28-04 PILHLE-001: neoadjuvant pyrotinib combined with chemotherapy in HR-positive, HER2-low (IHC 2+/FISH-negative) early breast cancer.
作者：Chang Gong，Yuan Xia，Yingying Zhu，Yaping Yang ，Wenqian Yang，Louis W.C. Chow，Li Ling，Yunjie Zeng，Jiajie Zhong，Ziliang Cheng， Jun Shen，Qun Lin，Yinduo Zeng，Qiang Liu，Erwei Song
第一作者单位：Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
PO1-28-07 Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HNBC-001): results from a multicenter, randomized controlled, open-label phase II trial.
作者：Dechuang Jiao，Jianghua Qiao，Chengzheng Wang，Juntao Li，Xianfu Sun，Zhenduo Lu，Chongjian Zhang，Lianfang Li，Min Yan， Yueqing Feng，Yong Zhou，Miao Deng，Xinlan Liu，Mingde Ma，Haiquan Jia，Qingxin Xia，Xiuchun Chen，Zhenzhen Liu
第一作者单位：Department of Breast Disease, Henan Breast Cancer Center. The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
PO1-28-08 The Efficacy and Safety Results of Neoadjuvant Phase II study of Anlotinib plus Sintilimab Combined with Chemotherapy in Triple-negative Breast Cancer (NeoSACT).
作者：Liulu Zhang，Mei Yang ，Ciqiu Yang，Teng Zhu，Hong-Fei Gao，Kun Wang
第一作者单位：Department of Breast Cancer, Cancer Center, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
PO1-29-02 Two and a half years follow-up data of HER2-targeted bispecific antibody KN026 combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer.
作者：Qingyuan Zhang，Jingxuan Wang， Quchang Ouyang，Xiaojia Wang，Jingfen Wang ，Lu Gan，Daren Lin，Zhong Ouyang，Ting Xu ，Yilan Liu，Yuan Lv
第一作者单位：Harbin Medical University Cancer Hospital
PO1-29-03 Efficacy, Safety, and Immunogenicity of TQ-B211 (a Trastuzumab Biosimilar) Plus Docetaxel versus Herceptin® Plus Docetaxel for HER2-positive Metastatic Breast Cancer: a Double-blind, Randomised, Multicenter, Phase 3 Trial.
作者：Xichun Hu，Qingyuan Zhang，Shusen Wang，Tao Sun ，Xiaohua Zeng，Weimin Xie，Zhongsheng Tong，Hui Cao，Huihua Xiong，Xiuwen wang ，Jin Yang，Shuqun Zhang，Ying Wang，Chunhong Hu，Kaijian Lei，Binlin Ma， Wei Liu，Zhiyong Yu，PeiJian Peng，Hongwei Yang，Zhijun Yuan，Xiaojia Wang，Xujuan Wang，Hong Wang，Yongqian Shu，Nanlin Li，Wenbin Yue，Jingfen Wang，Daqing Wang， Zhiguo Luo，Junyang Mo，Yarong Li，Lili Sheng
第一作者单位：Shanghai Cancer Center, Fudan University, China
SABCS中国之声总览：
Rapid Fire Session: Mini-Oral Presentations、POSTER SPOTLIGHT Session
本文检索了POSTER SESSIONS中第一作者单位为中国单位的研究。如果有任何错误或遗漏，请联系我们进行修改。
http://www.sabcs.org/FullProgram
排版编辑：肿瘤资讯-张薪媛
苏公网安备 32059002004080号
